This month, we talk to Dr Wen Hwa Lee, Strategic Alliances Manager at the Structural Genomics Consortium (SGC), part of the Nuffield Department of Clinical Medicine, about how the SGC is revolutionising the way we think about drug discovery.
Pan-Canadian Team of Researchers Will Receive CA$11.7 Million in Funding from Stand Up To Cancer Canada, Genome Canada, Canadian Institutes of Health Research, Cancer Stem Cell Consortium, and Ontario Institute for Cancer Research
Myeloma UK and the Structural Genomics Consortium (SGC) have entered into an open-access research partnership to discover and characterise novel drug targets for myeloma using structural biology and chemical proteomics.
This SRC is focused on the role of Methylation Dynamics in nuclear and cytoplasmic biological processes and how this modification impacts development, epigenetic cellular identity, tissue homeostasis and disease.
During DPhG Annual Meeting 2015 which took place in Düsseldorf September 23-25, 2015, the German Pharmaceutical Society honoured a few up-and-coming young scientists.
University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases -- thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation. The new funding brings the total investment from the Bill & Melinda Gates Foundation to nearly US $12 million since 2012.
Takeda Pharmaceutical Company Limited (Takeda) today announced it has renewed its partnership with the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to patients faster.
MONTREAL, Nov. 18, 2015 /CNW/ - AbbVie today announced its continued commitment to the Structural Genomics Consortium (SGC) by providing a cash sponsorship of CDA$7.5 million towards open access research leading to the discovery of new medicines. Today`s announcement coincides with meetings with Ontario and Quebec-based research leaders and AbbVie global research and development business development professionals to assess continued investment.
Ponatinib is an anti-cancer drug which has earned some notoriety for its cost (£90,000 per patient per year) and side-effects that were serious enough to temporarily suspend its use. But the findings from a recent Cell Chemistry and Biology paper led by the Structural Genomics Consortium suggest that this 'dirty' drug might actually hold the key for coming up with newer, more effective drugs for chronic illnesses such as Crohn's and Inflammatory Bowel Disease.
The Oxford Science Blog asked the first author, Dr Peter Canning (who worked on this study while at the Nuffield Department of Medicine) to explain what they found.